Amber Goodchild

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif
    Amber Goodchild
    Johnson and Johnson Research Pty Ltd, Eveleigh, NSW, 1430, Australia
    Nucleic Acids Res 35:4562-72. 2007
  2. ncbi Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death
    Mary Margaret Gozar
    Johnson and Johnson Research Pty Limited, Eveleigh, New South Wales, 1430, Australia
    Oligonucleotides 18:257-68. 2008
  3. ncbi Primary leukocyte screens for innate immune agonists
    Amber Goodchild
    Johnson and Johnson Research Pty Ltd, Strawberry Hills NSW, Australia
    J Biomol Screen 14:723-30. 2009
  4. ncbi Interfering ribonucleic acids that suppress expression of multiple unrelated genes
    Toby Passioura
    Johnson and Johnson Research Pty Ltd, Sydney, Australia
    BMC Biotechnol 9:57. 2009
  5. ncbi The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity
    Laurent Rivory
    Johnson and Johnson Research Pty, Ltd, Eveleigh, NSW, 1430, Australia
    Oligonucleotides 16:297-312. 2006
  6. ncbi Sequence determinants of innate immune activation by short interfering RNAs
    Amber Goodchild
    Johnson and Johnson Research Pty Ltd, Strawberry Hills, NSW, Australia
    BMC Immunol 10:40. 2009

Detail Information

Publications6

  1. ncbi Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif
    Amber Goodchild
    Johnson and Johnson Research Pty Ltd, Eveleigh, NSW, 1430, Australia
    Nucleic Acids Res 35:4562-72. 2007
    ....
  2. ncbi Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death
    Mary Margaret Gozar
    Johnson and Johnson Research Pty Limited, Eveleigh, New South Wales, 1430, Australia
    Oligonucleotides 18:257-68. 2008
    ....
  3. ncbi Primary leukocyte screens for innate immune agonists
    Amber Goodchild
    Johnson and Johnson Research Pty Ltd, Strawberry Hills NSW, Australia
    J Biomol Screen 14:723-30. 2009
    ..These assays are highly sensitive and provide a physiologically relevant system for the identification of a broad range of immunostimulant agents...
  4. ncbi Interfering ribonucleic acids that suppress expression of multiple unrelated genes
    Toby Passioura
    Johnson and Johnson Research Pty Ltd, Sydney, Australia
    BMC Biotechnol 9:57. 2009
    ..We have investigated the possibility of using a single short synthetic duplex RNA to suppress the expression of VEGF-A and ICAM-1; genes implicated in the progression of ocular neovascular diseases such as diabetic retinopathy...
  5. ncbi The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity
    Laurent Rivory
    Johnson and Johnson Research Pty, Ltd, Eveleigh, NSW, 1430, Australia
    Oligonucleotides 16:297-312. 2006
    ..These data reveal that the biologic activity of several published DNAzymes is not mediated through the catalytic degradation of target mRNA...
  6. ncbi Sequence determinants of innate immune activation by short interfering RNAs
    Amber Goodchild
    Johnson and Johnson Research Pty Ltd, Strawberry Hills, NSW, Australia
    BMC Immunol 10:40. 2009
    ....